Back to news overview

Ablynx announces positive topline results

Ablynx recently announced that it had received positive topline results for their study on patients with moderately to severely active rheumatoid arthritis (RA) who are intolerant to methotrexate or for whom continued methotrexate treatment is inappropriate. De Tijd published an article on the Belgian biotech sector. Click the links below to read all about it.

Sources: De Tijd , Ablynx' website